Research programme: engineered platelets-like cells - PlatletBio
Latest Information Update: 28 Jan 2026
At a glance
- Originator PlateletBio
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anti-N-methyl-D-aspartate receptor encephalitis; Membranoproliferative glomerulonephritis; Myasthenia gravis; Neuromyelitis optica; Thrombotic thrombocytopenic purpura
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for research development in Anti-N-methyl-D-aspartate-receptor-encephalitis in USA (Parenteral)
- 28 Jan 2026 No recent reports of development identified for research development in Membranoproliferative glomerulonephritis in USA (Parenteral)
- 28 Jan 2026 No recent reports of development identified for research development in Myasthenia-gravis in USA (Parenteral)